Publications:

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.

Clinical And Translational Medicine

Xu, Gehan G; Cui, Liang L; Li, Jin J; Wang, Quanren Q; Li, Pansong P; Xia, Xuefeng X; Yi, Xin X; Guan, Quanlin Q; Xu, Jianming J

Publication Date: 2022-10

Variant appearance in text: CLIP4: 2000G>T; G667V

PubMed Link: 36245284

Variant Present in the following documents:

• CTM2-12-e1086-s010.xlsx, sheet 4

View BVdb publication page